Research Article

Effect of PCSK9 Inhibitor on Contrast-Induced Acute Kidney Injury in Patients with Acute Myocardial Infarction Undergoing Intervention Therapy

Table 1

Comparison of baseline data between those who received evolocumab and controls.

Control group (n = 160)Evolocumab group (n = 149)χ2/t/Z value

Male sex, n (%)120 (75.0)102 (68.46)1.630.20
Age (years), mean, SD64.15, 10.7362.49, 10.451.380.17
STEMI, n (%)103 (64.38)99 (66.44)0.150.70
Old MI, n (%)28 (17.50)26 (17.45)<0.010.99
Diabetes mellitus, n (%)58 (36.25)57 (38.26)0.130.72
Hypertension, n (%)88 (55.00)96 (64.43)2.850.09
SBP (mmHg), median (IQR)134.00 (123.00–145.00)134.00 (123.00–145.00)−0.140.89
DBP (mmHg), median (IQR)78.00 (70.00–89.00)78.00 (70.00–88.75)−0.600.55
Atorvastatin, n (%)91 (56.88)80 (53.69)0.320.57
RAAS inhibitors, n (%)143 (89.38)126 (84.56)1.590.21
Killip class I, n (%)157 (98.13)141 (94.63)2.740.10
LVEF (%), median (IQR)50.00 (45.00–56.00)51.50 (46.00–56.00)−0.870.39
NT-pro-BNP (ng/L), median (IQR)684.00 (206.20–1582.00)719.60 (328.65–1510.00)−0.570.57
TNT (ng/mL), median (IQR)1.74 (0.64–3.39)1.43 (0.43–3.11)−1.430.15
Hb (g/L), median (IQR)133.00 (125.00–145.00)134.00 (122.25–145.00)−0.010.99
Hs-CRP (mg/L), median (IQR)6.34 (2.25–23.10)5.01 (2.13–13.67)−1.160.25
HDL-C (mmol/L), median (IQR)1.03 (0.87–1.24)1.00 (0.83–1.20)−1.110.27
LDL-C (mmol/L), median (IQR)3.17 (2.51–3.87)3.23 (2.43–4.24)−0.020.99
Contrast agent (mL), median (IQR)140.00 (130.00–150.00)140.00 (120.00–150.00)−0.730.47
Emergency PCI, n (%)103 (64.38)99 (66.44)0.150.70
Preoperative hydration, n (%)43 (26.88)29 (19.46)2.370.12
Postoperative hydration, n (%)157 (98.13)147 (98.66)0.140.71
Iodixanol, n (%)154 (96.25)118 (79.19)21.29<0.01

χ2/t/Z, a test used to compare parameters; SD, standard deviation; STEMI, acute ST-segment elevation myocardial infarction; MI, myocardial infarction; SBP, systolic blood pressure; IQR, interquartile range; DBP, diastolic blood pressure; RAAS, renin-angiotensin-aldosterone system; LVEF, left ventricular ejection fraction; NT-pro-BNP, N-terminal probrain natriuretic peptide; TNT, troponin T; Hb, hemoglobin; hs-CRP, high-sensitivity C-reactive protein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PCI, percutaneous coronary intervention.